Direkt zum Inhalt

Riedl, Moritz ; Witzmann, Christina ; Koch, Matthias ; Lang, Siegmund ; Kerschbaum, Maximilian ; Baumann, Florian ; Krutsch, Werner ; Docheva, Denitsa ; Alt, Volker ; Pfeifer, Christian

Attenuation of Hypertrophy in Human MSCs via Treatment with a Retinoic Acid Receptor Inverse Agonist

Article

Riedl, Moritz , Witzmann, Christina, Koch, Matthias, Lang, Siegmund, Kerschbaum, Maximilian , Baumann, Florian , Krutsch, Werner, Docheva, Denitsa , Alt, Volker and Pfeifer, Christian (2020) Attenuation of Hypertrophy in Human MSCs via Treatment with a Retinoic Acid Receptor Inverse Agonist. International Journal of Molecular Sciences 21 (4), p. 1444.

DOI to cite this document: 10.5283/epub.43034


Abstract

In vitro chondrogenically differentiated mesenchymal stem cells (MSCs) have a tendency to undergo hypertrophy, mirroring the fate of transient "chondrocytes" in the growth plate. As hypertrophy would result in ossification, this fact limits their use in cartilage tissue engineering applications. During limb development, retinoic acid receptor (RAR) signaling exerts an important influence on cell ...

In vitro chondrogenically differentiated mesenchymal stem cells (MSCs) have a tendency to undergo hypertrophy, mirroring the fate of transient "chondrocytes" in the growth plate. As hypertrophy would result in ossification, this fact limits their use in cartilage tissue engineering applications. During limb development, retinoic acid receptor (RAR) signaling exerts an important influence on cell fate of mesenchymal progenitors. While retinoids foster hypertrophy, suppression of RAR signaling seems to be required for chondrogenic differentiation. Therefore, we hypothesized that treatment of chondrogenically differentiating hMSCs with the RAR inverse agonist, BMS204,493 (further named BMS), would attenuate hypertrophy. We induced hypertrophy in chondrogenic precultured MSC pellets by the addition of bone morphogenetic protein 4. Direct activation of the RAR pathway by application of the physiological RAR agonist retinoic acid (RA) further enhanced the hypertrophic phenotype. However, BMS treatment reduced hypertrophic conversion in hMSCs, shown by decreased cell size, number of hypertrophic cells, and collagen type X deposition in histological analyses. BMS effects were dependent on the time point of application and strongest after early treatment during chondrogenic precultivation. The possibility of modifing hypertrophic cartilage via attenuation of RAR signaling by BMS could be helpful in producing stable engineered tissue for cartilage regeneration.



Involved Institutions


Details

Item typeArticle
Journal or Publication TitleInternational Journal of Molecular Sciences
PublisherMDPI
Open Access TypeGold (with APC)
Place of PublicationBASEL
Volume21
Number of Issue or Book Chapter4
Page Rangep. 1444
Date20 February 2020
Date of publication26 Mar 2020 15:18
InstitutionsMedicine > Lehrstuhl für Unfallchirurgie
Identification Number
ValueType
10.3390/ijms21041444DOI
KeywordsMESENCHYMAL STEM-CELLS; COLLAGEN GENE-EXPRESSION; IN-VITRO CHONDROGENESIS; BONE-MARROW; HETEROTOPIC OSSIFICATION; MOLECULAR-MECHANISMS; CARTILAGE FORMATION; ACTIVE REPRESSION; BINDING-PROTEINS; SYNOVIAL JOINT; mesenchymal stem cells; chondrogenesis; hypertrophy; BMS; retinoic acid receptor; inverse agonist
Dewey Decimal Classification600 Technology > 610 Medical sciences Medicine
StatusPublished
RefereedYes, this version has been refereed
Created at the University of RegensburgYes
URN of the UB Regensburgurn:nbn:de:bvb:355-epub-430347
Item ID43034

Export bibliographical data

Owner only: item control page

nach oben